TXR-311 Shows Promising Preclinical Efficacy and Safety in Hepatocellular Carcinoma

June 26, 2020

TXR-311 has demonstrated activity in validation studies and has selectivity for killing hepatocellular carcinoma tumor cells.

Exploring the Future Treatment Landscape of Hepatocellular Carcinoma

June 05, 2020

Richard S. Finn, MD, discusses how he sees the field of hepatocellular carcinoma evolving in the future.

Ilson Explores Treatment Options for Patients With Metastatic HCC

June 01, 2020

In a Targeted Oncology case-based peer perspectives live discussion, David H. Ilson, MD, PhD, discusses the treatment options for patients with hepatocellular carcinoma

FDA Approves Atezolizumab Combo for Unresectable or Metastatic Hepatocellular Carcinoma

May 29, 2020

“For the first-time we have a regimen that markedly improves survival over sorafenib, the standard of care for first-line hepatocellular carcinoma since 2007, and offers patients the opportunity for improved disease control with a favorable tolerability profile.”

Exploring Current and Upcoming Therapies for Hepatocellular Carcinoma

May 20, 2020

David J. Pinato, MD, PhD, discusses past and current trials that are significant for the hepatocellular carcinoma patient population.

Cabozantinib May Be a Match for Regorafenib in Second line Advanced HCC

May 19, 2020

Based on data from a matching-adjusted indirect comparison study, cabozantinib the safety and efficacy of cabozantinib may be comparative to regorafenib in advanced hepatocellular carcinoma.

Personalized Treatment for Subtypes of HCC Is the Way of the Future

May 13, 2020

In an interview with Targeted Oncology, Yujin Hoshida, MD, PhD, discussed the next steps for improving upon the current understanding of hepatocellular carcinoma subtypes to improve responses and outcomes in patients.

Evaluating Current Challenges in Hepatocellular Carcinoma

May 07, 2020

Anjana Pillai, MD, discusses challenges for treating patients with hepatocellular carcinoma.

FDA Grants Orphan Drug Designation to First Liver-Targeted Drug for HCC

May 06, 2020

"Having obtained an encouraging proof-of-concept for the liver-cancer directed effect of MIV-818 in phase Ia, we hope to get additional supportive data from the phase Ib study. We believe that MIV-818 has the potential to provide liver cancer patients with major therapeutic benefits."

Expert Reviews TKI Survival Data as Therapy for HCC

April 24, 2020

“If we’re going to get patients to second-line treatment, we have to get them to front line. That has to do with transitioning patients from locoregional therapy appropriately."